Arvinas (ARVN) to Release Quarterly Earnings on Tuesday

Arvinas (NASDAQ:ARVN - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.87) per share and revenue of $34.42 million for the quarter.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 10.92% and a negative return on equity of 7.74%. During the same period in the previous year, the firm earned ($0.97) EPS. The company's revenue for the quarter was up 646.2% compared to the same quarter last year. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Up 1.2%

Arvinas stock traded up $0.10 during midday trading on Thursday, hitting $7.97. The company's stock had a trading volume of 755,634 shares, compared to its average volume of 2,179,497. The stock's 50-day moving average price is $7.38 and its 200-day moving average price is $10.90. The company has a market capitalization of $581.37 million, a PE ratio of -12.08 and a beta of 2.17. Arvinas has a 12 month low of $5.90 and a 12 month high of $30.24.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ARVN shares. Barclays cut their price objective on Arvinas from $32.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Morgan Stanley cut their price objective on Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Leerink Partnrs downgraded Arvinas from a "strong-buy" rating to a "hold" rating in a report on Sunday, June 1st. BTIG Research set a $16.00 target price on Arvinas and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, UBS Group lowered their target price on Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $20.29.

Insider Activity

In other news, CFO Andrew Saik sold 5,700 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the transaction, the chief financial officer directly owned 164,401 shares of the company's stock, valued at $1,251,091.61. The trade was a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.73% of the stock is owned by corporate insiders.

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC increased its position in shares of Arvinas by 208.4% during the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company's stock valued at $9,198,000 after acquiring an additional 885,483 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Arvinas by 108.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company's stock worth $6,339,000 after acquiring an additional 469,394 shares during the period. AQR Capital Management LLC bought a new position in shares of Arvinas in the first quarter worth $727,000. Jacobs Levy Equity Management Inc. bought a new stake in Arvinas during the first quarter valued at $301,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Arvinas by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock valued at $271,000 after buying an additional 2,122 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.